WASHINGTON, DC – Rep. Edward J. Markey (D-Mass), Chairman of the Subcommittee on Energy and Environment, and Rep. Fred Upton (R-Mich.), the Ranking Member of the Subcommittee, hailed Wednesday’s (October 21st) passage of the American Medical Isotopes Production Act, H.R. 3276, out of the full Energy and Commerce Committee.  The bipartisan legislation addresses the ongoing crisis in nuclear medicine by ensuring that a robust and reliable supply of the most critical medical isotopes is produced in the United States. The Markey-Upton bill will ensure that this isotope, and the life-saving procedures it enables, will once again be fully available to U.S. patients.

“Problems abroad have exposed troublesome flaws here at home in nuclear medicine – our nation must produce these life saving isotopes to protect the public health,” said Upton.  “Today, we are a step closer to ensuring the tens of thousands of Americans who seek diagnosis and treatment every day for afflictions such as heart disease and cancer promptly receive the care they need.  With our most reliable supply of medical isotopes currently out of commission, the clock is ticking and the wellbeing of countless folks hangs in the balance.”

In addition, the bill will lead more reactors around the world to convert away from weapons-usable highly enriched uranium (HEU).  The importance of converting reactors at home and abroad away from the use of HEU has been recently highlighted by the negotiations over providing fuel for Iran’s medical isotope reactor, which was originally fueled with HEU.

“Today the Committee has taken a major step towards insuring an uninterrupted supply of critical medical isotopes,” said Markey. “Every day, medical isotopes fuel thousands of potentially life-saving medical tests across the country. We owe it to doctors and patients to ensure the supply never runs out. We cannot afford to have American patients held hostage to old and faulty nuclear reactors in other countries for these materials.”

The American Medical Isotopes Production Act has been endorsed by:
•    The Council on Radionuclides and Radiopharmaceuticals (CORAR)
•    The Society for Nuclear Medicine
•    The American Association of Physicists in Medicine
•    The American College of Radiology
•    The American College of Cardiology
•    The American Society of Nuclear Cardiology
•    The Health Physics Society
•    Lantheus Medical Imaging
•    Covidien
•    Astellas Pharma US
•    GE Hitachi
•    Babcock and Wilcox
•    University of Missouri
•    The Union of Concerned Scientists
•    Physicians for Social Responsibility
•    Nuclear Threat Initiative
•    Nonproliferation Policy Education Center

The medical isotope technetium-99m, a decay product of molybdenum-99, is used for 50,000 procedures a day in the United States, including for the detection and staging of cancer and the detection of heart disease.  However, the United States does not currently produce these critical isotopes, and is reliant upon foreign producers for a constant supply.

In May, the Canadian reactor which usually supplies 60 percent of US demand broke down, leaving American patients in danger and forcing American doctors to replace technecium-99m procedures with alternatives that are less effective, more costly, and potentially more dangerous to both patients and doctors.  Even worse, the world’s second-largest medical isotope producer is also in need of repair. The High-Flux Reactor (HFR) at Petten in the Netherlands will be off-line for at least three months beginning in March of 2010, triggering an extended period of extraordinarily low supply leading to rationing of medical procedures in the United States.  The repairs at HFR Petten, coupled with the problems at the Canadian reactor, will reduce total production capacity to approximately 10 percent of normal levels.

The bill also will close a long-neglected loophole in U.S. nuclear nonproliferation law, by ending the export of highly enriched uranium for medical isotope production.  Highly enriched uranium is nuclear bomb material, and the national security of the United States demands that we never export it again.  However, medical isotopes can be made just as effectively with low enriched uranium.  This year, the National Academy of Sciences concluded in an authoritative study that there are “no technical reasons that adequate quantities cannot be produced” without the use of highly enriched uranium.

The American Medical Isotopes Production Act will provide resources and authority to the Department of Energy to bring domestic production of this critical isotope on-line as soon as possible.  The bill authorizes $163 million over five years, which fully funds the current Department of Energy cost projection for creating a robust domestic molybdenum-99 production capacity.  The Department of Energy is required to use this money to support private sector or research sector projects to establish molybdenum-99 production.  The bill also provides the Department of Energy with new authorities to assist in the development of fuels, targets, and processes for domestic molybdenum-99 production.  Additionally, the bill will responsibly end the export of U.S. highly enriched uranium in 7-11 years, providing sufficient time for less dangerous technologies to be substituted.

Source:  News release from Congressman Fred Upton